Immunic (Immunic) Operating Cash Flow per Share : $-1.60 (TTM As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Immunic Operating Cash Flow per Share?

Immunic's operating cash flow per share for the three months ended in Dec. 2023 was $-0.32. Immunic's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.60.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 39.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 38.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Immunic's Operating Cash Flow per Share or its related term are showing as below:

IMUX' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -48.1 Med: 23.15 Max: 58.3
Current: 18.4

During the past 13 years, Immunic's highest 3-Year average Operating Cash Flow per Share Growth Rate was 58.30% per year. The lowest was -48.10% per year. And the median was 23.15% per year.

IMUX's 3-Year OCF Growth Rate is ranked better than
66.51% of 1242 companies
in the Biotechnology industry
Industry Median: 3.75 vs IMUX: 18.40

Immunic Operating Cash Flow per Share Historical Data

The historical data trend for Immunic's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunic Operating Cash Flow per Share Chart

Immunic Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-3.70

-2.95

-3.52

-2.05

-1.60

Immunic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.39	-0.45	-0.45	-0.39	-0.32

Competitive Comparison of Immunic's Operating Cash Flow per Share

For the Biotechnology subindustry, Immunic's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunic's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunic's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Immunic's Price-to-Operating-Cash-Flow falls into.

Immunic Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Immunic's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-70.828	/	44.320
	=	-1.60

Immunic's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-14.027	/	44.598
	=	-0.31

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.60

Immunic Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Immunic's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunic (Immunic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunic Inc (NAS:IMUX) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

10VA:Germany

Address

1200 Avenue of the Americas, Suite 200, New York, NY, USA, 10036

Website

https://www.imux.com

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.

Executives

Glenn Whaley	officer: PAO and Controller	C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Richard Alan Rudick	director	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK NY 10036
Joerg Neermann	director	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Daniel Vitt	director, officer: CEO, President	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Monika Maria Toernsen	director	ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Duane Nash	director	C/O VITAL THERAPIES, INC., 15010 AVENUE OF SCIENCE, SUITE 200, SAN DIEGO CA 92128
Andreas Muehler	officer: Chief Medical Officer	1200 AVENUE OF THE AMERICAS, SUITE 200, NEW YORK CITY NY 10036
Manfred Groeppel	officer: Chief Operating Officer	IMMUNIC AG, AM KLOPFERSPITZ 19, MARTINSRIED 2M 82152
Barclay A Phillips	director	C/O CANCER VAX CORP, 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Tamar D Howson	director
Sanjay S Patel	officer: Chief Financial Officer	10 N. PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Claudio Nessi	10 percent owner	C/O NEOMED, 7 PLACE DU MOLARD, 1204 GENEVA V8 1204
Anne-mari Paster	10 percent owner	C/O OMEGA FUND MANAGEMENT, LLC, 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Omega Fund V Gp, L.p.	10 percent owner	888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Lsp V Cooperatieve U.a.	10 percent owner	JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV